Yeast was the very first non-bacterial organism to have all of its genes sequenced, and the collaborative nature of the EU-funded breakthrough laid the foundations for the sequencing of the human genome less than 10 years later.
Unlocking the DNA of Saccharomyces cerevisiae, a species of yeast used in winemaking, baking and brewing, began through the EU’s Biotechnology Action Plan (BAP) in 1989. Led by Belgian biologist André Goffeau, a total of 147 researchers from 35 laboratories linked forces to sequence chromosome III, one of the 16 chromosomes found in yeast, with the groundbreaking results published in 1992.
‘Without the European funds, I don’t think the project would have happened at all. It certainly wouldn’t have moved as fast as it did,’ said Professor Stephen Oliver, now of Cambridge University, UK, who led the team.
‘Sequencing chromosome III … provided the keys to unlock the genetic potential of yeast.’
Professor Stephen Oliver, Cambridge University, UK
‘Sequencing chromosome III … provided the keys to unlock the genetic potential of yeast and other organisms, because we could define what was there and begin to study the function of genes that, previously, we didn’t even know existed,’ he said.
Mapping the remaining 15 yeast chromosomes was completed with further Framework Programme support for an even wider consortium of researchers in the EU, the US, Japan and Canada, and published in 1996.
Funding from BAP’s successors – the BRIDGE and BIOTECH programmes – helped to identify the functions of specific yeast genes. That was crucial in understanding similar genes in humans, and laid the foundations for sequencing the entire human genome, which was completed in 2003.
Having a blueprint of the inner workings of yeast has been all-important in identifying and developing new strains for making beers and wines with particular flavours or lower alcohol, or to be used in hotter production regions.
New yeast varieties have also helped in efforts to reduce reliance on fossil fuels, through biofuels such as industrial ethanol and biodiesel from plant matter or waste from wood processing.
In medicine, the yeast genome map has allowed yeast to be used to produce new medications and vaccines, and in understanding diseases such as colon cancer and cystic fibrosis. It has also played an important role in developing treatments such as gene therapy.
‘I think the synergy among yeast researchers within Europe was hugely boosted by the chromosome III project and the genome project,’ Prof. Oliver said. ‘The collaborations outlived the sequencing project itself and have continued through other projects.’
To celebrate three decades of the European Commission, Commissioner Carlos Moedas and Director-General Robert-Jan Smits discuss its achievements and current focus, Horizon 2020.
Thousands of metres below the Atlantic Ocean live strange types of coral that no human has ever set eyes on. Or at least that was true until last year, when a group of researchers began investigating the uncharted abyss with a remotely-operated vehicle.
Nearly 100 years ago scientists developed a vaccine for tuberculosis (TB). Today, there are 10 million new cases worldwide and 1.6 million deaths from the disease every year. Increasingly, these cases are becoming difficult to treat as the bug that causes the disease can be resistant to antibiotics. However, several new TB vaccines are under development and there is growing optimism that a new vaccine will emerge, says Helen McShane, professor of vaccinology at Oxford University, UK. This could save millions of lives, she said, but more work is needed to reassure the general public that vaccines are safe and effective.
Forests have a special magic for many of us. Steeped in folklore and fantasy, they are places for enchantments, mythical creatures and outlaws. But if they are to survive into the future, they may also need a helping hand from science.
Tuberculosis is the most common cause of death from an infectious disease.
Computer modelling will also help optimise management techniques.
Entrepreneur Nicklas Bergman on the European Innovation Council.